Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARROS-1: NVL-520 in Advanced ROS1-positive Solid Tumors
2024-511793-71-00Phase 2Authorised
- Sponsor
- Nuvalent
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label trial of zidesamtinib in non-small cell lung cancer (NSCLC) and solid neoplasms (2 arms), sponsored by Nuvalent. Primary endpoints: Phase 1: Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) and Phase 2: Objective Response Rate (ORR). Planned start Apr 2024; status: authorised.
02
Drugs
zidesamtinib
03
Conditions
non-small cell lung cancer (NSCLC)solid neoplasms
Beyond the preview
Go deeper on 2024-511793-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511793-71-00.